Retrospective assessment of everolimus treatment in patients suffering from advanced renal cell carcinoma

• Authors: Paweł Hernik , Maksymilian Kruczała , Marek Ziobro
• Languages of publication: EN

Abstracts

EN

Objective: Results of second-line everolimus treatment in clear cell renal carcinoma. Material and methods: Clinical data of 32 patients of the Clinic of Systemic and Metastatic Malignancies, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute (Krakow Branch) treated with second-line everolimus between 2011 and 2016 were analysed. Results: Median progression-free survival was 7 months. Stable disease was observed in 24 cases. Adverse events occurred in 59% of all patients, and the majority were mild and moderate (G1 and G2) according to CTCAE. The most frequent adverse events included anaemia, stomatitis, rash and fatigue. Conclusion: Molecularly targeted drugs offer the only effective and available therapy in Poland, which can be administered in patients with advanced renal cell carcinoma. Second-line everolimus is a valuable therapeutic option in the above mentioned group (following progression on first-line TKI therapy), especially when it is necessary to avoid the accumulation of similar adverse events after TKI treatment (different toxicity profiles).

Keywords

EN

everolimus; renal cell carcinoma; targeted therapy

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2017
• Volume: 7
• Issue: 2
• Pages: 88-91

Contributors

author

Paweł Hernik

• Clinic of Systemic and Metastatic Malignancies, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow Branch

author

Maksymilian Kruczała

• Clinic of Systemic and Metastatic Malignancies, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow Branch

author

Marek Ziobro

• Clinic of Systemic and Metastatic Malignancies, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow Branch

References

• 1. Ferlay J, Shin HR, Bray F et al. International Agency for Research on Cancer, Lyon, France 2010 [online: www.globocan.iarc.fr].
• 2. National Cancer Registry [online: http://onkologia.org.pl/nowotwory-zlosliwe-nerki-c67/].
• 3. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (ed.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press: Lyon 2004.
• 4. Hemal AK, Kumar A, Kumar R et al. Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. J Urol 2007; 177(3): 862-866.
• 5. Berger A, Brandina R, Atalla MA et al. Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more. J Urol 2009; 182: 2172-2176.
• 6. Delakas D, Karyotis I, Daskalopoulos G. et al. Nephron-sparing surgery for localized renal cell carcinoma with a normal contralateral kidney: a European three-center experience. Urology 2002; 60(6): 998-1002.
• 7. MacLennan S, Imamura M, Lapitan MC et al. Systematic review of oncological outcomes following surgical management of localised renal cancer. Eur Urol 2012; 61: 972-993.
• 8. Wu Z, Li M, Liu B et al. (Coppola D. ed.). Robotic versus Open Partial Nephrectomy: A Systematic Review and Meta-Analysis. PLoS ONE 2014; 9(4): e94878. DOI: 10.1371/journal.pone.0094878.
• 9. Gitlitz BJ, Figlin RA. Cytokine-based therapy for metastatic renal cell cancer. Urol Clin North Am 2003; 30(3): 589-600.
• 10. Rosenberg SA, Yang JC, White DE et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228(3): 307-319.
• 11. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6 (suppl 1): S55.
• 12. Coppin C, Prozsolt R, Awa A et al. Immunotherapy for advanced renal cell cancer. Cohrane Database Sys Rev 2005; 1: CD001425.
• 13. de Reijke TM, Bellmunt J, van Poppel H et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009; 45(5): 765-773.
• 14. Heng DY, Xie W, Regan MM et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013; 14(2): 141-148.
• 15. Chrom P, Stec R, Semeniuk-Wojtas A et al. Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors. Clin Genitourin Cancer 2016; 14(5): 457-464.
• 16. Treatment of malignant kidney neoplasms (ICD-10 C 64) – drug reimbursement programme of the Ministry of Health. [online: http://www.mz.gov. pl/leki/refundacja/programy-lekowe/].
• 17. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010 15; 116(18): 4256-4265.
• 18. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373: 1803-1813.
• 19. Choueiri TK, Escudier B, Powles T et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, openlabel, phase 3 trial. Lancet Oncol 2016; 17: 917-927.

• Document Type: article